Decoding the synaptic dysfunction of bioactive human AD brain soluble Aβ to inspire novel therapeutic avenues for Alzheimer’s disease

por Li, Shaomin, Jin, Ming, Liu, Lei, Dang, Yifan, Ostaszewski, Beth L., Selkoe, Dennis J.
Publicado 2018

Aph-1 Associates Directly with Full-length and C-terminal Fragments of γ-Secretase Substrates

por Chen, Allen C., Guo, Lucie Y., Ostaszewski, Beth L., Selkoe, Dennis J., LaVoie, Matthew J.
Publicado 2010

Target engagement in an alzheimer trial: Crenezumab lowers amyloid β oligomers in cerebrospinal fluid

por Yang, Ting, Dang, Yifan, Ostaszewski, Beth, Mengel, David, Steffen, Verena, Rabe, Christina, Bittner, Tobias, Walsh, Dominic M., Selkoe, Dennis J.
Publicado 2019

Plasma N-terminal tau fragment levels predict future cognitive decline and neurodegeneration in healthy elderly individuals

por Chhatwal, Jasmeer P., Schultz, Aaron P., Dang, Yifan, Ostaszewski, Beth, Liu, Lei, Yang, Hyun-Sik, Johnson, Keith A., Sperling, Reisa A., Selkoe, Dennis J.
Publicado 2020

Secreted Amyloid β-Proteins in a Cell Culture Model Include N-Terminally Extended Peptides That Impair Synaptic Plasticity

por Welzel, Alfred T., Maggio, John E., Shankar, Ganesh M., Walker, Donald E., Ostaszewski, Beth L., Li, Shaomin, Klyubin, Igor, Rowan, Michael J., Seubert, Peter, Walsh, Dominic M., Selkoe, Dennis J.
Publicado 2014

Evaluating the Safety and Efficacy of Crenezumab vs Placebo in Adults With Early Alzheimer Disease: Two Phase 3 Randomized Placebo-Controlled Trials

por Ostrowitzki, Susanne, Bittner, Tobias, Sink, Kaycee M., Mackey, Howard, Rabe, Christina, Honig, Lawrence S., Cassetta, Emanuele, Woodward, Michael, Boada, Mercè, van Dyck, Christopher H., Grimmer, Timo, Selkoe, Dennis J., Schneider, Andres, Blondeau, Kathleen, Hu, Nan, Quartino, Angelica, Clayton, David, Dolton, Michael, Dang, Yifan, Ostaszewski, Beth, Sanabria-Bohórquez, Sandra M., Rabbia, Michael, Toth, Balazs, Eichenlaub, Udo, Smith, Jillian, Honigberg, Lee A., Doody, Rachelle S.
Publicado 2022